PAASHEUVELWEG 25A, AMSTERDAM, P7
Announces Pricing of Upsized $300 Million Public Offering
News, Material Contracts
Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
News, Underwriting Agreement, Legal Opinion
Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
Provides Regulatory Update on AMT-130 for Huntington’s Disease
Announces First Quarter 2025 Financial Results and Highlights of Recent Progress
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report